Evaxion Biotech A/S (EVAX) to Release Quarterly Earnings on Tuesday

Evaxion Biotech AS is a Norwegian biotechnology company focused on developing and commercializing therapeutic vaccines for infectious diseases and cancer. The company's primary focus is on developing a therapeutic vaccine for tuberculosis (TB), which is one of the world's leading causes of death due to a single infectious agent.

On Tuesday, Evaxion Biotech AS is scheduled to release its quarterly earnings report for the third quarter of 2022. The earnings report will provide insights into the company's financial performance during this period, including revenue, expenses, and net income or loss.

Investors and analysts will closely watch the report for any updates on the company's progress in developing its TB vaccine candidate, EVX-01. The vaccine is currently in Phase 2 clinical trials and has shown promising results in preclinical and early clinical studies. The vaccine is designed to stimulate a strong immune response against TB, which could potentially lead to more effective treatment and prevention of the disease.

Additionally, investors will be looking for any updates on partnerships or collaborations that Evaxion may have entered into during the quarter. The company has previously announced collaborations with institutions such as the University of Oslo and the University of Copenhagen to advance its research and development efforts.

The earnings report will also provide insights into the company's financial position and cash burn rate, which will be important for investors to assess the company's ability to continue funding its operations and bring its vaccine candidate to market.

Overall, the release of Evaxion Biotech AS's quarterly earnings report on Tuesday will provide valuable information for investors and analysts interested in the company's progress in developing its TB vaccine and its financial performance during the quarter.